Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide

Robert M. RifkinUS Oncology Research, Inc., The Woodlands, TX, USA; Correspondence[email protected]

Rafat AbonourIndiana University Cancer Center, Indianapolis, IN, USA;

Jatin J. ShahDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Jayesh MehtaDivision of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA;

Mohit NarangMaryland Oncology Hematology, Columbia, MD, USA;

Howard TerebeloProvidence Cancer Center Institute, Southfield, MI, USA;

Cristina GasparettoDivision of Cellular Therapy, Duke University Medical Center, Durham, NC, USA;

Kathleen ToomeySteeplechase Cancer Center, Somerville, NJ, USA;

James W. HardinEpidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA;

Jane Jie LuCelgene Corporation, Summit, NJ, USA;

Laurie KenvinCelgene Corporation, Summit, NJ, USA;

Shankar SrinivasanCelgene Corporation, Summit, NJ, USA;

Robert KnightCelgene Corporation, Summit, NJ, USA;

Yasir NagarwalaCelgene Corporation, Summit, NJ, USA;

Brian G. M. DurieCedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA

References